CTRI/2017/03/008023
Completed
未知
Real world, Non-interventional, Observational Study of Venusia® Max Cream as Moisturizer in Psoriasis
ConditionsHealth Condition 1: null- Psoriasis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Psoriasis
- Sponsor
- Dr Reddys Laboratories Ltd
- Enrollment
- 400
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients with psoriasis who have been prescribed Venusia® Max cream
- •2\.Patients of both sexes, aged 18 years to 75 years who provide informed consent for data collection
Exclusion Criteria
- •1\.Those with known hypersensitivity to any ingredient of Venusia® Max cream
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical trial to observe the safety and effectiveness of acotiamide in patients with functional dyspepsiaCTRI/2017/11/010421Dr Reddys Laboratories Limited
Not yet recruiting
Not Applicable
Study to analyse usefulness of antibacterial (Chlorhexidine) containing mouthwash for the treatment of swollen and bleeding gums.Health Condition 1: K051- Chronic gingivitisCTRI/2019/04/018353Dr Reddys Laboratories Ltd
Recruiting
Phase 4
Study the effectiveness of Hydroxyzine hydrochloride in Patients with Persistent ItchingHealth Condition 1: null- Chronic PruritusCTRI/2017/06/008847Dr Reddys Laboratories Ltd400
Completed
Not Applicable
Prospective, Non-interventional Observational Study at the Influence of Malnutrition on Nosocomial Infections in Patients During Early Neurological RehabilitatioE46B99Unspecified protein-energy malnutritionOther and unspecified infectious diseasesDRKS00000617Schoen-Klinik Bad Aibling100
Active, not recruiting
Phase 4
A study to evaluate safety and effectiveness of Rivaroxaban (Xarelto®) forPrevention of Stroke and Systemic Embolism in IndianPatients with Non-valvular Atrial Fibrillation (NVAF)Health Condition 1: I489- Unspecified atrial fibrillation and atrial flutterCTRI/2019/09/021158Bayer Zydus Pharma Private Limited